Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.

Tee, Andrew E; Ciampa, Olivia C; Wong, Matthew; Fletcher, Jamie I; Kamili, Alvin; Chen, Jingwei; Ho, Nicholas; Sun, Yuting; Carter, Daniel R; Cheung, Belamy B; Marshall, Glenn M; Liu, Pei Y; Liu, Tao

Tee, Andrew E; Ciampa, Olivia C; Wong, Matthew; Fletcher, Jamie I; Kamili, Alvin; Chen, Jingwei; Ho, Nicholas; Sun, Yuting; Carter, Daniel R; Cheung, Belamy B; Marshall, Glenn M; Liu, Pei Y; Liu, Tao.

Afiliação

Tee AE; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Ciampa OC; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Wong M; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Fletcher JI; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Kamili A; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Chen J; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Ho N; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Sun Y; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Carter DR; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Cheung BB; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Marshall GM; School of Women's and Children's Health, UNSW Sydney, Randwick, New South Wales, Australia.
Liu PY; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Liu T; Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.

Int J Cancer ; 147(7): 1928-1938, 2020 10 01.

Article em En | MEDLINE | ID: mdl-32086952

Assuntos

Proteína Proto-Oncogênica N-Myc/genética; Neuroblastoma/genética; Fenilenodiaminas/farmacologia; Inibidores de Proteínas Quinases/farmacologia; Pirimidinas/farmacologia; Linhagem Celular Tumoral; Proliferação de Células/efeitos dos fármacos; Sobrevivência Celular/efeitos dos fármacos; Quinases Ciclina-Dependentes/antagonistas & inibidores; Proteínas de Ligação a DNA/genética; Proteínas de Ligação a DNA/metabolismo; Regulação para Baixo; Sinergismo Farmacológico; Amplificação de Genes; Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos; Humanos; Imidazóis/farmacologia; Lapatinib/farmacologia; Neuroblastoma/tratamento farmacológico; Neuroblastoma/metabolismo; Piridazinas/farmacologia; Proteínas de Ligação a RNA/genética; Proteínas de Ligação a RNA/metabolismo; Quinase Ativadora de Quinase Dependente de Ciclina

Palavras-chave

CDK7; N-Myc; PNUTS; THZ1; neuroblastoma; tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fenilenodiaminas / Pirimidinas / Inibidores de Proteínas Quinases / Proteína Proto-Oncogênica N-Myc / Neuroblastoma Limite: Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google